MetaCap

Benitec Biopharma (BNTC) vs Evommune (EVMN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Benitec Biopharma (BNTC) has outperformed Evommune (EVMN) over the past year, losing 40.3% versus a loss of 62.4%. Evommune is the larger company by market cap ($291.1 million vs $285.9 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BNTC-40.31%EVMN-62.37%
+76%-2%-80%
Nov 21, 20251 yearNov 20, 2026
BNTC-38.12%EVMN-61.76%
+79%-0%-79%
Nov 3, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BNTC versus EVMN key metrics
MetricBNTCEVMN
Share price$7.92$7.04
Market cap$285.88M$291.10M
1-day change-2.76%-2.76%
YTD return-41.24%-58.88%
1-year return-40.31%-62.37%
5-year return-85.67%—
EPS (TTM)$-1.02$-3.83
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$13.00M
Revenue growth (YoY)—+85.71%
Net income (latest FY)$-45.55M$-68.87M
Operating margin—-623.62%
Net margin—-529.77%
52-week high$14.39$33.20
52-week low$7.72$4.94
Distance from 52-week high-45.00%-78.80%
Analyst consensusstrong_buybuy
Avg. price target upside+200.06%+210.94%
Average volume174.01K841.65K
Shares outstanding36.12M41.35M
Employees2448
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • BNTC has outperformed EVMN by 22.1 percentage points over the past year.

About Benitec Biopharma

BNTC stock →

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines in the United States. Its Silence and Replace, a DNA-directedRNA interference platform, that combines RNA interference with gene therapy to create medicines which simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct.

Health Care · Biotechnology: Pharmaceutical Preparations · 24 employees

About Evommune

EVMN stock →

Evommune, Inc. operates as a clinical-stage biotechnology company in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees

BNTC vs EVMN FAQ

Which is bigger, Benitec Biopharma or Evommune?

Evommune (EVMN) is larger, with a market capitalization of $291.10M compared with $285.88M for Benitec Biopharma (BNTC).

Which stock has performed better over the past year, BNTC or EVMN?

BNTC returned -40.31% over the past 12 months, compared with -62.37% for EVMN (price return, excluding dividends). Past performance does not predict future results.

Are Benitec Biopharma and Evommune in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons